Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]

Sections

• ABBREVIATIONS AND GLOSSARY
• EXECUTIVE SUMMARY
• 1. CONTEXT AND POLICY ISSUES
• 2. POLICY QUESTIONS
• 3. RESEARCH QUESTIONS
• 4. METHODS
• 5. RESULTS
• 6. DISCUSSION
• 7. CONCLUSIONS AND IMPLICATIONS FOR DECISION-OR POLICY-MAKING
• REFERENCES
• APPENDIX 1. PATIENT INPUT INFORMATION
• APPENDIX 2. VALIDITY OF OUTCOMES
• APPENDIX 3. LITERATURE SEARCH STRATEGY
• APPENDIX 4. SELECTION OF INCLUDED STUDIES
• APPENDIX 5. INCLUDED STUDY LIST
• APPENDIX 6. EXCLUDED STUDY LIST
• APPENDIX 7. CHARACTERISTICS OF INCLUDED STUDIES
• APPENDIX 8. CRITICAL APPRAISAL OF INCLUDED STUDIES
• APPENDIX 9. DETAILED DATA OF MONOTHERAPY AND ADD-ON THERAPY TRIALS
• APPENDIX 10. PAIRWISE META-ANALYSES
• APPENDIX 11. COMPARISONS OF PAIRWISE META-ANALYSES AND NETWORK META-ANALYSES
• APPENDIX 12. COMPLETE RESULTS OF NETWORK META-ANALYSIS
• APPENDIX 13. QUALITY OF LIFE
• APPENDIX 14. COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION — STUDIES NOT INCLUDED IN THERAPEUTIC REVIEW
• APPENDIX 15. REVIEW OF PREVIOUS PHARMACOECONOMIC ANALYSES
• APPENDIX 16. SCHEMATIC OF MARKOV MODEL
• APPENDIX 17. CLINICAL PARAMETERS FOR THE ECONOMIC MODEL
• APPENDIX 18. RESOURCE USE ESTIMATES FOR THE ECONOMIC MODEL
• APPENDIX 19. BREAKDOWN OF COSTS BY COST CATEGORY